There are a couple of risks though that are associated with COVID, right. So ultimately -- we have yet to see it, but there potentially can be an impact in terms of the initial diagnosis of patients with AML. Though it's [Indecipherable] emergent disease, the reluctance of patients to show up could potentially manifest over time, but we haven't seen that significantly as of yet. The continued work from home restrictions on the sales force can potentially add some pressure. But what we've seen also is an increase in Medicaid and 340B utilization as well. And we would expect that to continue as Andrew indicated earlier.